Enterprise Value

1.955B

Cash

296.3M

Avg Qtr Burn

-79.19M

Short % of Float

22.07%

Insider Ownership

5.20%

Institutional Own.

97.21%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
REC-2282 Details
Neurofibromatosis Type 2-mutated meningiomas

Phase 2/3

Data readout

REC-4881 Details
Familial Adenomatous Polyposis

Phase 2

Data readout

Phase 2

Data readout

REC-994 Details
Cerebral cavernous malformation

Phase 2

Data readout

REC-3964 Details
Clostridium difficile Colitis

Phase 2

Initiation

REC-3599 Details
GM2 gangliosidosis

Failed

Discontinued